Venus Medtech HangZhou Inc (Venus MedTech) is a medical device company that develops and commercializes transcatheter heart valve products for structural heart diseases. The company's product portfolio includes venusA- valve, venusP- valve, V8/TAV8, and TriGUARD3 CEP device. Its products find applications in transcatheter aortic valve replacement systems, anti-embolic distal brain protection devices, TAV8 balloon dilatation catheter, transcatheter prosthetic pulmonary valve systems, TMVr&TTVr mitral and tricuspid valve repair and replacement, RDN therapy, hypertrophic cardiomyopathy, transcatheter pulmonary valve replacement, transcatheter mitral valve replacement and transcatheter tricuspid valve replacement mainly associated with aortic stenosis and pulmonic, mitral and tricuspid regurgitation. Venus MedTech is headquartered in Hangzhou, Zhejiang, China.
Headquarters
China
Address
Room 311, 3/F, Block 2, No. 88, Jiangling Road, Binjiang District, Hangzhou, Zhejiang
Website
www.venusmedtech.com
No of Employees
1,006
Industry
Medical Equipment
Ticker Symbol & Exchange
2500 (HKG)
Revenue (2022)
$60.4M
-2.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-183.1%
(2022 vs 2021)
Market Cap*
$316.2M
Net Profit Margin (2022)
XYZ
-189.6%
(2022 vs 2021)
* As of and is in US$
Venus Medtech Hangzhou Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| VenusP-Valve | Customer Services |
| VenusA-valve | Technical Support |
| V8/TAV8 | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In February, the company secured approval from Health Canada for VenusP-Valve. |
| 2023 | Regulatory Approval | In August, the company received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to conduct a clinical trial for the VenusP-Valve. |
| 2022 | Others | In April, the company’s VenusP-Valve received CE marking under the Medical Devices Regulation (MDR) to be marketed in Europe. |
Competitor Comparison
| Key Parameters | Venus Medtech Hangzhou Inc | Edwards Lifesciences Corp | Colibri Heart Valve LLC | LivaNova Japan KK |
|---|---|---|---|---|
| Headquarters | China | United States of America | United States of America | Japan |
| City | Hangzhou | Irvine | Louisville | Tokyo City |
| State/Province | Zhejiang | California | Colorado | Tokyo |
| No. of Employees | 1,006 | 17,300 | - | - |
| Entity Type | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Min Frank Zeng | Chairman | Executive Board | - | 60 |
| Zhenjun Zi | General Manager; Executive Director | Executive Board | 2012 | 53 |
| Meirong Liu | Vice President; Director | Executive Board | - | 47 |
| Liqiao Ma | Director | Executive Board | 2023 | - |
| Haiyue Ma | Secretary; Chief Financial Officer | Senior Management | - | 45 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward